Bayer Agrees to Suspend Marketing of Trasylol

WASHINGTON, D.C. - The FDA said today that Bayer Pharmaceuticals Corp. has agreed to a request to suspend marketing of the company's Trasylol blood-clotting drug because of an increased risk of death.

The Nov. 5 announcement comes on the heels of a Canadian study that was halted prematurely after reports of increased mortality among study participants administered the drug, compared to those who received similar agents.

"FDA requested the suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data [from the Canadian study]," the FDA said in a statement.

News …